Genmont Biotech Overview

  • Founded
  • 2000

  • Status
  • Public

  • Employees
  • 147

  • Stock Symbol
  • 3164

Stock Symbol
  • Share Price
  • $0.85

  • (As of Wednesday Closing)

Genmont Biotech General Information


GenMont Biotech Inc is engaged in the research, development, manufacturing and selling of a variety of probiotic supplements.

Contact Information

Ownership Status
Publicly Held
Financing Status
Primary Industry
Stock Exchange
Primary Office
  • No.8, Tainan Science-Based Industrl Prk Nan-Ke
  • 7th Road Shanhua District
  • Shanhua, 741
  • Taiwan
+886 06 000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Genmont Biotech Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.85 $0.84 $0.65 - $0.98 $73.1M 86.4M 104K $0.02

Genmont Biotech Financials Summary

In Thousands,
TTM 31-Mar-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 62,496 59,432 69,975 59,586
Revenue 11,762 12,379 15,313 11,048
EBITDA 3,169 3,783 5,701 3,278
Net Income 1,380 1,914 4,048 2,068
Total Assets 55,844 55,278 61,326 57,822
Total Debt 1,133 1,126 1,182 1,231
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Genmont Biotech Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Genmont Biotech‘s full profile, request access.

Request a free trial

Genmont Biotech Patents

Genmont Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230081322-A1 Lactobacillus composition and use thereof for improving anxiety caused by antibiotics Pending 06-Sep-2021 000000000 0
US-20220031775-A1 Probiotic composition and method for improving an effect of chemotherapeutic drug of gemcitabine on inhibiting pancreatic cancer Pending 29-Jul-2020 0000000000 0
US-20210213076-A1 Lactobacillus paracasei gmnl-346 for anti-oral cancer treatment and thereof Pending 14-Jan-2020 0000000000
US-10639336-B1 Use of a probiotic composition for preventing stroke and ameliorating the severity of stroke Active 10-Jun-2019 0000000000
US-20200077692-A1 Lactobacillus composition for inhibiting gastritis induced by gastric helicobacter pylori and use thereof Active 12-Sep-2018 A61P1/04
To view Genmont Biotech’s complete patent history, request access »

Genmont Biotech Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial